The aim of this report was to determine the frequency of thrombocytopenia in a cohort of 1,126 patients receiving oral anticoagulant therapy (OAT), and to compare the grade of thrombocytopenia and the severity of bleeding complications. Severe thrombocytopenia was observed in five patients, and moderate and light thrombocytopenia were observed in 208 patients. Thrombocytopenic patients receiving OAT presented five major and six minor hemorrhages. The presence of hepatitis markers and autoantibodies was assessed. All parameters at the time of the bleeding complication were in the therapeutic range.
Oral anticoagulant therapy represents an unusual treatment of different pathologic conditions. Improvements in heart surgery greatly increased the number of patients with valvular prosthesis or other types of surgical operations that require extended or lifelong anticoagulation therapy (1) . Recent knowledge about thromboembolism associated with genetic thrombophilic defects (factor V Leiden, prothrombin mutation, and hyperhomocysteinemia) determined new therapeutic conduct (2, 3) . Attention must be set now for prophylaxis in patients who are carriers of genetic thrombophilic alterations to protect them from more serious events (4). Antiphospholipid syndrome is the most common acquired condition associated with vein or arterial thrombosis (5) . The result of these studies is the continuous increase in the number of patients receiving OAT. Various studies aimed at assessing the hemorrhagic risk during OAT (6, 7) . The aim of our study was to evaluate the frequency of thrombocytopenia in a cohort of 1,126 patients receiving OAT and the correlated incidence of the hemorrhagic syndrome (8) .
MATERIALS AND METHODS
We examined all the patients receiving OAT from August 1, 2000 to July 31, 2001. We evaluated 1,126 patients. Table 1 shows the different pathologic conditions that required OAT.
We investigated liver functionality, hepatitis markers, and autoantibodies in patients with a platelet count lower than normal in two consecutive controls. Patients with possible systemic severe blood diseases were excluded from the study. The two coumarin drugs available in Italy were warfarin, 757 patients (67.2%); and acenocoumarol, 369 patients (32.8%). The patients with thrombocytopenia were compared with a control group to evaluate the clinical bleeding symptoms. RESULTS We found thrombocytopenia in 213 patients (18.9% of all patients); (125 males and 88 females) aged between 13 and 92 years old (9). Bleeding complications were observed, as shown in Table 3 , in 11 thrombocytopenic patients. Major hemorrhagic complications consisted of two intracranial hemorrhages (13) (14) (15) , two gastric hemorrhages, and one hemarthrosis; minor episodes were one conjunctival, two epistaxis, one menorrhagia, and two cutaneous purpuras. Any hemorrhagic complications were not fatal.
DISCUSSION
We observed 185 with mild thrombocytopenia (100-150 x 109/L), 23 moderate (50-100 x 109/L) and 5 severe (<50 x 109/L) ( Table 2 ).
Thrombocytopenia was found in 132 patients (62%) with warfarin and in 81 patients (38%) with acenocoumarol (difference not statistically significant). Table 2 shows the results related to thrombocytopenia grade according to the indication for OAT (10) (11) (12) .
We evaluated 88 patients with thrombocytopenia and hepatitis viruses (HBV and HCV): 56 (63.6%) of these test results were negative and 32 (36.4%) were positive (17 HBV+, 9 HCV+, and 6 HBV and HCV+). Autoantibodies (ANA, ASMA, AMA, APCA, cANCA, pANCA, ENA) were
We observed a high incidence of thrombocytopenia in patients receiving OAT. Thrombocytopenia could represent an additional hemorrhagic risk in these patients.
Two of the five patients with severe thrombocytopenia showed bleeding symptoms; one was intracranial and the minor one was menorrhagia. Major bleeding episodes occurred in four cases of light and moderate thrombocytopenia. All major complications required hospital admission; one patient received a blood transfusion. We interrupted OAT in all major complications. Minor complications needed only a reduction of OAT. All patients with thrombocytopenia had an international normalized ratio in therapeutic range at the time of bleeding complications. A good cor- relation was observed between the incidence of thrombocytopenia and positivity to the markers of hepatitis and autoantibodies; the HBV/HCV positivity was more frequent in patients undergoing surgery for valvular prosthesis or arterial bypass. No correlation was observed between the grade of thrombocytopenia and HCV, HBV, and autoantibodies. Bleeding complications in OAT patients without thrombocytopenia were significantly fewer when compared with those in the examined patients (Table 4 ).
In conclusion we think that clinical oversight and more accurate monitoring of therapy are important in patients receiving oral anticoagulant therapy with moderate or severe thrombocytopenia. The severity of thrombocytopenia determines, in percentage, a greater hemorrhagic risk compared to moderate and mild thrombocytopenia. Another finding of this study is that patients undergoing surgery showed a high frequency of positivity to hepatitis markers and thrombocytopenia. These patients require intense observation. 
